{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:03:46Z","timestamp":1789549426598,"version":"build-2803163510"},"reference-count":33,"publisher":"American Chemical Society (ACS)","issue":"7","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>MTA-cooperative inhibition of protein arginine methyltransferase 5 (PRMT5) is synthetic lethal with methylthioadenosine phosphorylase (MTAP)-deficient cancers. PRMT5\u2032s enzymatic activity can be assessed by measuring symmetric dimethylarginine (SDMA) modification levels of protein substrates. However, conventional assays that attempt to measure total SDMA levels lack the specificity to measure individual PRMT5 substrates, and thus potentially reduce selectivity and sensitivity. This study aims to identify and characterize specific DMA peptides that can serve as clinical pharmacodynamic (PD) biomarkers for PRMT5 inhibition in formalin-fixed paraffin-embedded solid tumors, leveraging data-independent acquisition-mass spectrometry (DIA-MS)-based global proteomics without additional DMA enrichment. We evaluated 145 DMA peptides in xenograft models treated by a novel MTAP-selective PRMT5 inhibitor, AZD3470. Arginine dimethylation of G3BP1 at residue R460 (G3BP1(R460)) was identified as the primary PD biomarker for PRMT5 inhibition due to its high abundance and significant post-treatment reduction that correlated with dose. The global proteomics assay with a limit of detection\/quantification characterized the quantitative performance and allowed for confident detection of G3BP1(R460). Using this quantitative assay, more than 90% reduction in G3BP1(R460) modification at 100 mg\/kg was reproducibly detected in MTAP-null xenograft models. Our findings suggested that the DIA-MS proteomics assay can provide high specificity and sensitivity in the detection of PRMT5 inhibition.<\/jats:p>","DOI":"10.1021\/acs.jproteome.6c00112","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:32:45Z","timestamp":1781919165000},"page":"3586-3594","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative\nGlobal Proteomics of Formalin-Fixed Paraffin-Embedded\nTumors Identifies Dimethylated G3BP1 at Arginine 460 as a Robust Pharmacodynamic\nBiomarker of Methylthioadenosine Phosphorylase-Selective Protein Arginine\nMethyltransferase 5 Inhibition"],"prefix":"10.1021","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7705-7360","authenticated-orcid":true,"given":"Anqi","family":"Tu","sequence":"first","affiliation":[{"name":"AstraZeneca , , , ,","place":["Gaithersburg, Maryland, United States, 20878"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2842-3549","authenticated-orcid":true,"given":"Elizabeth J","family":"Wiseman","sequence":"additional","affiliation":[{"name":"AstraZeneca , , ,","place":["Cambridge, U.K., CB2 0AA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3962-0421","authenticated-orcid":true,"given":"Steve M","family":"Sweet","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , ,","place":["Gaithersburg, Maryland, United States, 20878"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Urosevic","sequence":"additional","affiliation":[{"name":"Oncology Targeted Discovery, Oncology R&D , ,","place":["Cambridge, U.K., CB2 0AA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Loizou","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research , , ,","place":["London, U.K., SW7 3RP"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Barnicle","sequence":"additional","affiliation":[{"name":"AstraZeneca , , ,","place":["Cambridge, U.K., CB2 0AA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Richardson","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , ,","place":["Gaithersburg, Maryland, United States, 20878"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhanshu","family":"Abhishek","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , ,","place":["Gaithersburg, Maryland, United States, 20878"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Chain","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , ,","place":["Gaithersburg, Maryland, United States, 20878"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2648-2872","authenticated-orcid":true,"given":"Yeoun Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , ,","place":["Gaithersburg, Maryland, United States, 20878"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7030-5780","authenticated-orcid":true,"given":"Andrew G","family":"Chambers","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , ,","place":["Gaithersburg, Maryland, United States, 20878"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"5","key":"2026091520064073600_cit1","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s12276-021-00613-y","article-title":"Protein arginine\nmethyltransferases: promising targets for cancer therapy","volume":"53","author":"Hwang","year":"2021","journal-title":"Exp Mol. Med."},{"key":"2026091520064073600_cit2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13008-018-0036-2","article-title":"Protein arginine\nmethylation: an emerging regulator\nof the cell cycle","volume":"13","author":"Raposo","year":"2018","journal-title":"Cell Div"},{"issue":"10","key":"2026091520064073600_cit3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41580-019-0155-x","article-title":"The regulation, functions and clinical\nrelevance of\narginine methylation","volume":"20","author":"Guccione","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2026091520064073600_cit4","doi-asserted-by":"publisher","first-page":"6428","DOI":"10.1038\/ncomms7428","article-title":"PRMT9 is a type II methyltransferase\nthat methylates the splicing factor SAP145","volume":"6","author":"Yang","year":"2015","journal-title":"Nat. Commun."},{"issue":"3","key":"2026091520064073600_cit5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1369\/0022155413475452","article-title":"Overexpression of PRMT5 promotes\ntumor cell growth and is associated\nwith poor disease prognosis in epithelial ovarian cancer","volume":"61","author":"Bao","year":"2013","journal-title":"J. Histochem Cytochem"},{"issue":"12","key":"2026091520064073600_cit6","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e22088","article-title":"Pan-cancer\nanalysis identifies protein arginine methyltransferases\nPRMT1 and PRMT5 and their related signatures as markers associated\nwith prognosis, immune profile, and therapeutic response in lung adenocarcinoma","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"issue":"2","key":"2026091520064073600_cit7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.21037\/tcr.2019.03.05","article-title":"Role of PRMT5 in bladder cancer:\na comprehensive study","volume":"8","author":"Ma","year":"2019","journal-title":"Transl Cancer Res."},{"issue":"9","key":"2026091520064073600_cit8","doi-asserted-by":"publisher","first-page":"8728","DOI":"10.18632\/aging.103198","article-title":"High PRMT5\nexpression is associated with poor overall\nsurvival and tumor progression in bladder cancer","volume":"12","author":"Tan","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"8","key":"2026091520064073600_cit9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"issue":"3","key":"2026091520064073600_cit10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.36401\/JIPO-22-1","article-title":"Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors\nin Oncology Clinical Trials: A review","volume":"5","author":"Feustel","year":"2022","journal-title":"J. Immunother\nPrecis Oncol"},{"issue":"3","key":"2026091520064073600_cit11","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1021\/acs.jmedchem.1c01900","article-title":"Fragment-Based Discovery of MRTX1719, a Synthetic Lethal\nInhibitor of the PRMT5*MTA Complex for the Treatment of MTAP-Deleted\nCancers","volume":"65","author":"Smith","year":"2022","journal-title":"J. Med. Chem."},{"issue":"11","key":"2026091520064073600_cit12","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1158\/2159-8290.CD-23-0951","article-title":"Early Clinical\nSuccess of MTA-Cooperative PRMT5 Inhibitors for the Treatment of CDKN2A\/MTAP-Deleted\nCancers","volume":"13","author":"Mulvaney","year":"2023","journal-title":"Cancer Discov"},{"issue":"11","key":"2026091520064073600_cit13","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719\nIs an MTA-Cooperative PRMT5 Inhibitor That\nExhibits Synthetic Lethality in Preclinical Models and Patients with\nMTAP-Deleted Cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"issue":"12","key":"2026091520064073600_cit14","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1158\/1078-0432.CCR-05-2780","article-title":"Lack of methylthioadenosine phosphorylase expression\nin mantle cell lymphoma is associated with shorter survival: implications\nfor a potential targeted therapy","volume":"12","author":"Marce","year":"2006","journal-title":"Clin. Cancer\nRes."},{"issue":"16_suppl","key":"2026091520064073600_cit15","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1200\/JCO.2024.42.16_suppl.3067","article-title":"Nature and distribution of methyl\nthioadenosine phosphorylase (MTAP) genomic loss in human tumors","volume":"42","author":"Necchi","year":"2024","journal-title":"J. Clin Oncol"},{"issue":"6278","key":"2026091520064073600_cit16","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion\nconfers enhanced dependency on the PRMT5\narginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"issue":"6278","key":"2026091520064073600_cit17","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted\ncancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"issue":"16","key":"2026091520064073600_cit18","doi-asserted-by":"publisher","first-page":"13604","DOI":"10.1021\/acs.jmedchem.4c00097","article-title":"Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel\nPRMT5 Inhibitor with High MTA Cooperativity","volume":"67","author":"Smith","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026091520064073600_cit19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12014-020-09283-w","article-title":"Recent advances\nin mass spectrometry\nbased clinical proteomics: applications to cancer research","volume":"17","author":"Macklin","year":"2020","journal-title":"Clin Proteomics"},{"key":"2026091520064073600_cit20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12014-015-9102-9","article-title":"Advances\nin mass\nspectrometry-based clinical biomarker discovery","volume":"13","author":"Crutchfield","year":"2016","journal-title":"Clin Proteomics"},{"issue":"15\u201316","key":"2026091520064073600_cit21","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1002\/pmic.201500449","article-title":"Advances\nin targeted proteomics and\napplications to biomedical research","volume":"16","author":"Shi","year":"2016","journal-title":"Proteomics"},{"issue":"1","key":"2026091520064073600_cit22","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1021\/acs.jproteome.8b00699","article-title":"Data-Independent Acquisition Mass Spectrometry To Quantify\nProtein Levels in FFPE Tumor Biopsies for Molecular Diagnostics","volume":"18","author":"Kim","year":"2018","journal-title":"J. Proteome Res."},{"issue":"8","key":"2026091520064073600_cit23","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2024.100800","article-title":"Data-Independent\nAcquisition: A Milestone and Prospect in Clinical Mass Spectrometry-Based\nProteomics","volume":"23","author":"Frohlich","year":"2024","journal-title":"Mol. Cell Proteomics"},{"issue":"7\u20138","key":"2026091520064073600_cit24","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.202200238","article-title":"Clinical applications of mass spectrometry-based\nproteomics in cancer: Where are we?","volume":"23","author":"Boys","year":"2023","journal-title":"Proteomics"},{"issue":"9","key":"2026091520064073600_cit25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2022.100279","article-title":"Rapid and In-Depth Coverage of the (Phospho-)Proteome With Deep Libraries\nand Optimal Window Design for dia-PASEF","volume":"21","author":"Skowronek","year":"2022","journal-title":"Mol.\nCell Proteomics"},{"issue":"3","key":"2026091520064073600_cit26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1021\/acs.jproteome.9b00666","article-title":"Matrix-Matched Calibration Curves\nfor Assessing Analytical Figures of Merit in Quantitative Proteomics","volume":"19","author":"Pino","year":"2020","journal-title":"J. Proteome Res."},{"issue":"1","key":"2026091520064073600_cit27","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20199111","article-title":"Automated\nsample preparation with SP3 for low-input\nclinical proteomics","volume":"16","author":"Muller","year":"2020","journal-title":"Mol. Syst. Biol."},{"issue":"12","key":"2026091520064073600_cit28","doi-asserted-by":"publisher","first-page":"6855","DOI":"10.1093\/nar\/gkaa376","article-title":"G3BP1-linked mRNA partitioning supports selective protein synthesis\nin response to oxidative stress","volume":"48","author":"Somasekharan","year":"2020","journal-title":"Nucleic Acids\nRes."},{"key":"2026091520064073600_cit29","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2022.146294","article-title":"The roles of G3BP1\nin human diseases","volume":"821","author":"Ge","year":"2022","journal-title":"Gene"},{"issue":"4","key":"2026091520064073600_cit30","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/jnc.15280","article-title":"The multi-functional\nRNA-binding\nprotein G3BP1 and its potential implication in neurodegenerative disease","volume":"157","author":"Sidibe","year":"2021","journal-title":"J. Neurochem"},{"issue":"3","key":"2026091520064073600_cit31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/1061186X.2018.1523415","article-title":"The roles and mechanisms\nof G3BP1 in tumour promotion","volume":"27","author":"Zhang","year":"2019","journal-title":"J. Drug Target"},{"issue":"11","key":"2026091520064073600_cit32","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s41401-020-00598-w","article-title":"G3BP1 promotes\nhuman breast cancer cell proliferation through coordinating with GSK-3\u03b2\nand stabilizing \u03b2-catenin","volume":"42","author":"Zhang","year":"2021","journal-title":"Acta Pharmacol\nSin."},{"issue":"43","key":"2026091520064073600_cit33","doi-asserted-by":"publisher","first-page":"22671","DOI":"10.1074\/jbc.M116.739573","article-title":"Arginine Demethylation of G3BP1 Promotes\nStress Granule Assembly","volume":"291","author":"Tsai","year":"2016","journal-title":"J. Biol. Chem."}],"container-title":["Journal of Proteome Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jproteome.6c00112","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jprobs\/article-pdf\/25\/7\/3586\/65180158\/acs.jproteome.6c00112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jprobs\/article-pdf\/25\/7\/3586\/65180158\/acs.jproteome.6c00112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:09:49Z","timestamp":1789546189000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jprobs\/article\/25\/7\/3586\/5165361\/Quantitative-Global-Proteomics-of-Formalin-Fixed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,6,19]]},"published-print":{"date-parts":[[2026,7,3]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jproteome.6c00112","relation":{},"ISSN":["1535-3893","1535-3907"],"issn-type":[{"value":"1535-3893","type":"print"},{"value":"1535-3907","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]}}}